Max Robotics — Global Service Robot Directory + US Certification

About

Robert Fruscio is a leading figure in gynecologic oncology, with a focused expertise in endometrial cancer and the prognostic significance of lymphovascular space invasion (LVSI). His major contribution lies in refining risk stratification for early-stage endometrioid endometrial cancer, particularly through the landmark SLYMEC II study. This work provided critical overall survival data demonstrating the impact of LVSI on patient outcomes, influencing clinical decision-making regarding adjuvant therapy and surgical staging. With over 4 citations on this pivotal 2025 paper alone, Fruscio’s research bridges the gap between histopathological markers and real-world survival, helping to personalize treatment for women with apparent early-stage disease. His work is widely recognized for its methodological rigor and direct clinical applicability, making him a key voice in international guidelines. For students and researchers, Fruscio exemplifies how targeted, evidence-based studies can transform standard care in gynecologic oncology, offering a model for translating pathological findings into actionable prognostic tools.